Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: FDD8A6364B33EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Understanding

The DelveInsight Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology report gives a thorough understanding of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) in the US, Europe, and Japan. The report covers the detailed information of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology scenario in seven major countries (US, EU5, and Japan).

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Perspective by DelveInsight

The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Detailed Epidemiology Segmentation

The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology covered in the report provides historical as well as forecasted Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Report and Model provide an overview of the global trends of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
• The report provides the segmentation of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology

Report Highlights

• 11-year Forecast of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
• Cases of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) by Mutation Types
• Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)?
• What are the key findings pertaining to the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)?
• What are the currently available treatments of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)?

Reasons to buy

The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) market
• Quantify patient populations in the global Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) therapeutics in each of the markets covered
• Understand the magnitude of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) population by its epidemiology
• The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF FAMILIAL HYPERCHOLESTEROLEMIA (TYPE II HYPERLIPOPROTEINEMIA)

3. FAMILIAL HYPERCHOLESTEROLEMIA (TYPE II HYPERLIPOPROTEINEMIA): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Treatment and Management
6.2. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in 7MM (2019-2032)
Table 2: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in the United States (2019-2032)
Table 4: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in Germany (2019-2032)
Table 6: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in France (2019-2032)
Table 8: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in Italy (2019-2032)
Table 10: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in Spain (2019-2032)
Table 12: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in the United Kingdom (2019-2032)
Table 14: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in Japan (2019-2032)
Table 16: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in 7MM (2019-2032)
Figure 2 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in the United States (2019-2032)
Figure 4 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in Germany (2019-2032)
Figure 6 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in France (2019-2032)
Figure 8 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in Italy (2019-2032)
Figure 10 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in Spain (2019-2032)
Figure 12 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Epidemiology in Japan (2019-2032)
Figure 16 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report